Market Cap 7.10M
Revenue (ttm) 0.00
Net Income (ttm) -19.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,300
Avg Vol 14,432
Day's Range N/A - N/A
Shares Out 668,000.00
Stochastic %K 56%
Beta 1.09
Analysts Sell
Price Target $30.00

Company Profile

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 261 2900
Address:
70 Doppler, Irvine, United States
envvenomedical
envvenomedical Jul. 31 at 1:09 PM
$NVNO Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve https://envveno.com/envveno-medical-reports-second-quarter-2026-financial-results-and-advances-towards-fda-pivotal-trial-for-first-in-class-non-surgical-replacement-venous-valve/
0 · Reply
Icemanja
Icemanja Jul. 21 at 7:58 PM
$NVNO Volume finally showed up. When they will need that ATM soon !!!
0 · Reply
Icemanja
Icemanja Jul. 15 at 4:34 PM
$NVNO Betting Agianst Rob Berman was the only way to make money in anything he does no different this time around. The few investors that did take a chance on this company got burnt multiple times. No matter what PR they put out interest will be low. At this price and MC someone could control the whole float for 7 mil. Management reputation is whats dragging this company down.
0 · Reply
tuckerabbott
tuckerabbott Jul. 15 at 12:54 PM
$NVNO still garbage. This company is going nowhere. Do your DD first.
0 · Reply
VirtualInvestor
VirtualInvestor Jul. 15 at 12:52 PM
$NVNO CEO Highlights How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market in #VirtualInvestor #WhatThisMeans https://vimeo.com/1210160347/c11be2bcd4?fl=ip&fe=ec
0 · Reply
envvenomedical
envvenomedical Jul. 15 at 12:45 PM
$NVNO Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment https://envveno.com/envveno-medical-highlights-newly-issued-u-s-patent-strengthening-competitive-position-ahead-of-historic-pivotal-trial-in-virtual-investor-what-this-means-segment/
0 · Reply
envvenomedical
envvenomedical Jul. 7 at 12:49 PM
$NVNO Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial https://envveno.com/envveno-medical-secures-transformational-u-s-patent-for-envve-system-strengthening-competitive-moat-ahead-of-launch-of-historic-fda-pivotal-trial/
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 7 at 12:29 PM
$NVNO enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
0 · Reply
TopSarge
TopSarge Jun. 29 at 4:10 PM
$NVNO Watching how buyers respond
0 · Reply
envvenomedical
envvenomedical Jun. 24 at 12:55 PM
$NVNO Join us at 2:00 PM ET as we participate in the Webull Corporate Connect Virtual Webinar Series. Register Here: https://www.webull.com/webinar/detail/7f0b59cd13104f5ab186f2fc0685b6b9?__app_cfg__=%7B%22hideNav%22%3Atrue%7D
1 · Reply
Latest News on NVNO
enVVeno Medical sees cash runway into 3Q27

2026-07-31T12:41:17.000Z - 1 day ago

enVVeno Medical sees cash runway into 3Q27


enVVeno Medical highlights newly issued U.S. patent

2026-07-15T12:55:49.000Z - 17 days ago

enVVeno Medical highlights newly issued U.S. patent


enVVeno Medical secures U.S. patent for enVVe system

2026-07-07T12:45:24.000Z - 25 days ago

enVVeno Medical secures U.S. patent for enVVe system


enVVeno Medical upgraded to Buy from Neutral at Ladenburg

2026-07-06T15:05:07.000Z - 25 days ago

enVVeno Medical upgraded to Buy from Neutral at Ladenburg


enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year

2026-05-07T20:35:58.000Z - 3 months ago

enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year


enVVeno Medical sees cash runway into 3Q27

2026-05-07T20:34:39.000Z - 3 months ago

enVVeno Medical sees cash runway into 3Q27


enVVeno Medical trading halted, news pending

2026-01-17T00:50:35.000Z - 7 months ago

enVVeno Medical trading halted, news pending


enVVeno Medical board approves 1-for-35 reverse stock split

2026-01-15T13:20:22.000Z - 7 months ago

enVVeno Medical board approves 1-for-35 reverse stock split


enVVeno Medical Announces Reverse Stock Split

Jan 15, 2026, 8:00 AM EST - 7 months ago

enVVeno Medical Announces Reverse Stock Split


enVVeno Medical trading resumes

2025-11-13T22:30:26.000Z - 9 months ago

enVVeno Medical trading resumes


enVVeno Medical receives unfavorable FDA decision for VenoValve

2025-11-13T22:05:19.000Z - 9 months ago

enVVeno Medical receives unfavorable FDA decision for VenoValve


enVVeno Medical trading halted, news pending

2025-11-13T21:55:16.000Z - 9 months ago

enVVeno Medical trading halted, news pending


enVVeno Medical reports Q3 EPS (23c) vs. (35c) last year

2025-10-31T12:15:43.000Z - 9 months ago

enVVeno Medical reports Q3 EPS (23c) vs. (35c) last year


enVVeno Medical Updates Regulatory Status of VenoValve(R)

Sep 15, 2025, 8:45 AM EDT - 11 months ago

enVVeno Medical Updates Regulatory Status of VenoValve(R)


First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 7, 2021, 1:40 PM EDT - 5 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve


envvenomedical
envvenomedical Jul. 31 at 1:09 PM
$NVNO Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve https://envveno.com/envveno-medical-reports-second-quarter-2026-financial-results-and-advances-towards-fda-pivotal-trial-for-first-in-class-non-surgical-replacement-venous-valve/
0 · Reply
Icemanja
Icemanja Jul. 21 at 7:58 PM
$NVNO Volume finally showed up. When they will need that ATM soon !!!
0 · Reply
Icemanja
Icemanja Jul. 15 at 4:34 PM
$NVNO Betting Agianst Rob Berman was the only way to make money in anything he does no different this time around. The few investors that did take a chance on this company got burnt multiple times. No matter what PR they put out interest will be low. At this price and MC someone could control the whole float for 7 mil. Management reputation is whats dragging this company down.
0 · Reply
tuckerabbott
tuckerabbott Jul. 15 at 12:54 PM
$NVNO still garbage. This company is going nowhere. Do your DD first.
0 · Reply
VirtualInvestor
VirtualInvestor Jul. 15 at 12:52 PM
$NVNO CEO Highlights How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market in #VirtualInvestor #WhatThisMeans https://vimeo.com/1210160347/c11be2bcd4?fl=ip&fe=ec
0 · Reply
envvenomedical
envvenomedical Jul. 15 at 12:45 PM
$NVNO Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment https://envveno.com/envveno-medical-highlights-newly-issued-u-s-patent-strengthening-competitive-position-ahead-of-historic-pivotal-trial-in-virtual-investor-what-this-means-segment/
0 · Reply
envvenomedical
envvenomedical Jul. 7 at 12:49 PM
$NVNO Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial https://envveno.com/envveno-medical-secures-transformational-u-s-patent-for-envve-system-strengthening-competitive-moat-ahead-of-launch-of-historic-fda-pivotal-trial/
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 7 at 12:29 PM
$NVNO enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
0 · Reply
TopSarge
TopSarge Jun. 29 at 4:10 PM
$NVNO Watching how buyers respond
0 · Reply
envvenomedical
envvenomedical Jun. 24 at 12:55 PM
$NVNO Join us at 2:00 PM ET as we participate in the Webull Corporate Connect Virtual Webinar Series. Register Here: https://www.webull.com/webinar/detail/7f0b59cd13104f5ab186f2fc0685b6b9?__app_cfg__=%7B%22hideNav%22%3Atrue%7D
1 · Reply
envvenomedical
envvenomedical Jun. 23 at 7:30 PM
$NVNO will be participating in the Webull Corporate Connect Virtual Webinar Series tomorrow, June 24th at 2:00 PM ET. Tune in here: https://www.webull.com/webinar/detail/7f0b59cd13104f5ab186f2fc0685b6b9?__app_cfg__=%7B%22hideNav%22%3Atrue%7D
0 · Reply
envvenomedical
envvenomedical Jun. 22 at 1:39 PM
$NVNO to Present in the Webull Corporate Connect Webinar Series on Wednesday, June 24th at 2:00 PM ET Register here: https://www.webull.com/webinar/detail/7f0b59cd13104f5ab186f2fc0685b6b9?__app_cfg__=%7B%22hideNav%22%3Atrue%7D PR: https://envveno.com/envveno-medical-to-present-in-the-webull-corporate-connect-webinar-series/
1 · Reply
DegenStock
DegenStock Jun. 17 at 2:15 PM
$NVNO I’ve never seen a company have their own Stocktwits account to try to pump their own POS stock… if this isn’t a red flag, I don’t know what is. Probably Scumbag Berman behind the account. WORST CEO EVER, STEP DOWN. Everyone stay far away from this horrible company
1 · Reply
Icemanja
Icemanja Jun. 16 at 7:20 PM
$NVNO If this new product is so good insiders would switch to a shares compensation structure instead of cash payout to build trust and save money, after blowing up a 90mil MC. Hold your winners and cut your Losers.
0 · Reply
Icemanja
Icemanja Jun. 16 at 7:05 PM
$NVNO Had some time to waste and watched the segment. What a bunch of BS. Have they never heard of the placebo effect , they have zero provable proof the Venovalve worked apart from , what Berman said himself in the segment. " patient starts feeling better " . Yes they might have mitigated some of the issues Venovalve had with open surgery. But the concept of a standalone valve is still unproven , and they are basing this whole new trial on the same concept a Standalone valve to be the solution for CVI. They still think Venovalve is a success. How can you say a device is a success but can't prove it to the FDA. One question i have that Berman will never answer and JTC gets paid to smile and filter is. How did the results leak the day before the PR about failure, someone dumped 250k shares at market a day before the PR with 10k avg daily volume. Only very few retail buyers, institutional investors wont touch until they can get a deep discount. Even at this MC.
0 · Reply
envvenomedical
envvenomedical Jun. 4 at 6:44 PM
$NVNO 📅 Mark Your Calendar Join us on June 9th at 4 PM ET for a #VirtualInvestor Closing Bell segment featuring the latest company updates. Register here: https://us02web.zoom.us/webinar/register/WN_jpAkfamoQHuc2H0QWpVV_A#/registration
1 · Reply
envvenomedical
envvenomedical Jun. 2 at 1:35 PM
$NVNO to Participate in the Virtual Investor Closing Bell Series on Tuesday, June 9that 4:00 PM ET Register here: https://us02web.zoom.us/webinar/register/WN_jpAkfamoQHuc2H0QWpVV_A#/registration https://envveno.com/press-viewer/?i=166889
2 · Reply
Icemanja
Icemanja May. 12 at 11:59 PM
$NVNO " Buy some put it away and see what we do !! " Alot of us did Berman!! And your incompetency and lies cost us millions. From the CEO who currently owns 6,350 shares , Chief Medical Officer -2,500 and the show stopper Chief Technology Officer 0 . But wait this is the only company you'll hear the CEO say is in a lock our period for the last 3 year. And that they will continue to execute. I think he mean execute another failure and total investor capital wipe out.
0 · Reply
VirtualInvestor
VirtualInvestor May. 12 at 2:11 PM
$NVNO joined a #WhatThisMeans segment to discuss the FDA’s first-ever IDE approval for a U.S. pivotal study evaluating a non-surgical replacement venous valve and what this could mean for the ~3 million U.S. patients suffering from DVI. https://vimeo.com/1191510104/dade9c74de?share=copy&fl=sv&fe=ci
0 · Reply
SuperGreenToday
SuperGreenToday May. 12 at 1:04 PM
$NVNO Share Price: $9.88 Contract Selected: Aug 21, 2026 $2.5 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.13 – $0.16 Potential Upside: 63% ROI Time to Expiration: 100 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Vacuity
Vacuity May. 12 at 2:58 AM
$NVNO Berman trying to figure out how to squeeze every cent out of retail to line his pockets before this goes belly up
0 · Reply